Multiple sclerosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Given the morbidity and mortality associated with multiple sclerosis, as well as the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective. Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar. Controlling acute attack can reduce the economic burden of MS disease.

Given the morbidity and mortality associated with multiple sclerosis, as well as the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective.^[1]
Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar.^[2]
Controlling acute attack can reduce the economic burden of MS disease.^[3]

↑ Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM (September 2009). “Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis”. J Manag Care Pharm. 15 (7): 543–55. doi:10.18553/jmcp.2009.15.7.543. PMID 19739877.
↑ Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED (October 1998). “A comprehensive assessment of the cost of multiple sclerosis in the United States”. Mult. Scler. 4 (5): 419–25. doi:10.1177/135245859800400504. PMID 9839302.
↑ Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT (April 2005). “Cost of multiple sclerosis by level of disability: a review of literature”. Mult. Scler. 11 (2): 232–9. doi:10.1191/1352458505ms1137oa. PMID 15794399.